Shoulder Innovations, Inc.
NYSE:SIMedical - Specialties
-$0.13 today
- Market cap
- $432.04M
- Beta
- -1.07
- P/E (TTM)
- -8.4
- EPS (TTM)
- -$2.13
Volume 0.09M
Average 0.10M
SI Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Shoulder Innovations, Inc.NYSE: SI
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue growth accelerates
Q1 FY2026 revenue of $16.71M rose 64.9% year over year, ahead of the +55.9% change in trailing-twelve-month revenue. Sequentially, it rose 15.9% from the prior quarter.
Context
- Revenue increased in 2 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 3 analysts of $69.42M (+46.7%) for the fiscal year ending Dec 2026, a slowdown from the +49.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $16.71M+15.9% QoQ
- Last fiscal yearDec 2025
- $47.32M+49.6% YoY
- LTMMar 2026
- $53.89M+55.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +64.9% | +50.4% | -14.5 pp |
| 1 year | +49.6% | +46.7% | -2.9 pp |
| 3-year CAGR | — | +32.8% | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 47.32M USD
- Year-over-year change
- +49.6%
- 2-year CAGR
- +56.7%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 47.32M | +49.6% |
| FY2024 | 2024-12-31 | 31.62M | +64.1% |
| FY2023 | 2023-12-31 | 19.27M | — |
Revenue vs competitors
How SI compares with its peers on the latest reported figures
- SI's LTM Mar 2026 revenue of $53.89M is the 6th highest of the 11 companies compared; the peer median is $56.77M.
- Its year-over-year change of +55.9% is the 2nd highest of 8, against a peer median of +15.4%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $351.5M | +3.4% | -2.6% | |
| LTM Mar 2026 | $117.59M | +2.0% | +1.2% | |
| FY2025 | $107.88M | +19.8% | +42.8% | |
| LTM Mar 2026 | $71.1M | +121.1% | — | |
| LTM Mar 2026 | $69.21M | +7.4% | -8.8% | |
| LTM Mar 2026 | $53.89M | +55.9% | — | |
| LTM Mar 2026 | $44.33M | +22.5% | +38.1% | |
| LTM Dec 2025 | $13.02M | +15.4% | +14.9% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $0 | — | — |
| LTM Mar 2026 | $0 | — | — | |
| LTM Mar 2026 | $0 | — | — | |
| Peer median (excluding SI) | $56.77M | +15.4% | +8.0% | |
Competitors are the stored peer set for SI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Revenue | 19.27M | 31.62M | 47.32M |
| Cost of Revenue | 4M | 7.28M | 11.12M |
| Gross Profit | 15.27M | 24.34M | 36.2M |
| Gross Margin | 79.2% | 77.0% | 76.5% |
| Research & Development | 3.02M | 4.49M | 7.73M |
| Selling, General & Admin | 23.11M | 34.51M | 54.77M |
| Operating Expenses | 26.13M | 38.99M | 62.5M |
| Depreciation & Amortization | 1.64M | 2.2M | 3.21M |
| EBITDA | (10.25M) | (12.11M) | (37.08M) |
| EBITDA Margin | -53.2% | -38.3% | -78.4% |
| Operating Income | (10.86M) | (14.65M) | (26.3M) |
| Operating Margin | -56.4% | -46.3% | -55.6% |
| Interest Income | 0 | 0 | 0 |
| Interest Expense | 761K | 1.32M | 70K |
| Other Income / Expenses | (1.79M) | (966K) | (14.06M) |
| Income Before Tax | (12.66M) | (15.62M) | (40.36M) |
| Pre-Tax Margin | -65.7% | -49.4% | -85.3% |
| Income Tax Expense | 0 | 0 | 0 |
| Net Income | (12.66M) | (15.62M) | (40.36M) |
| Net Margin | -65.7% | -49.4% | -85.3% |
| EPS (Basic) | (0.63) | (0.77) | (1.96) |
| EPS (Diluted) | (0.63) | (0.77) | (1.96) |
| Weighted Avg Shares | 19.92M | 19.92M | 20.63M |
| Weighted Avg Shares (Diluted) | 19.92M | 19.92M | 20.63M |
Shoulder Innovations, Inc.
NYSE:SI
Intrinsic Alpha fair value
Locked
Current Price
$20.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.